Comparison of Progression Rate of Retinal Pigment Epithelium Loss in Patients with Neovascular Age-Related Macular Degeneration Treated with Ranibizumab and Aflibercept.
Purpose.Retinal pigment epithelium (RPE) loss in neovascular age-related macular degeneration (nAMD) seem to have a linear progression but might be influenced by the treatment. The purpose of the study is the comparison of RPE loss over three years in patients treated with intravitreal ranibizumab to patients who were switched to aflibercept.Methods.A retrospective analysis with 96 eyes switched to aflibercept was conducted. The progression rate of RPE loss was evaluated in patients who showed atrophy one year prior to switch (n= 17) or on switch date (n= 19). The RPE loss was evaluated by spectral domain optical coherence tomography (SD-OCT). Further, 22 eyes from patients treated with ranibizumab were compared.Results.The median yearly progression of RPE loss after square root transformation showed no significant difference in the year prior to switch compared to the year after switch (p= 0.854). In patients who received only ranibizumab, the median yearly progression of RPE loss was 0.15 mm/y, for aflibercept patients, 0.13 mm/y. This difference was not statistically significant (p= 0.172).Conclusions.There seems to be a linear progression rate of RPE loss in patients treated with ranibizumab as well as in patients with aflibercept. No significant increase of progression rate was found after switch to aflibercept.
City Hospital Triemli, Zurich, Switzerland.
Juliana
0000-0002-2194-126X
J
Wons
City Hospital Triemli, Zurich, Switzerland.
Magdalena A
MA
Wirth
Graf Biostatistics, Winterthur, Switzerland.
Nicole
N
Graf
City Hospital Triemli, Zurich, Switzerland.
Matthias D
MD
Becker
City Hospital Triemli, Zurich, Switzerland; University of Zurich, Zurich, Switzerland.
Stephan
S
Michels